Financial Performance - Total Revenue increased by 11% to $28045 million in H1 2025[9, 21] - Core EPS increased by 17% in H1 2025[9, 22] - Product Sales reached $26670 million in H1 2025, representing 95% of Total Revenue[21, 22] - Alliance Revenue contributed $1293 million to Total Revenue in H1 2025, accounting for 5%[21, 22] - Net cash inflow from operating activities increased by 27% in H1 2025[31] Pipeline and Approvals - 19 new approvals were obtained in key regions[9] - 12 positive Phase III readouts were achieved[9] - First Phase III data was reported for 5 NMEs[9] - Readouts across 2025 represent combined >$10 billion opportunity[14] Segment Performance - Oncology Total Revenue reached $120 billion in H1 2025, a 16% increase[36, 37] - BioPharmaceuticals Total Revenue was $66 billion in H1 2025, up by 10%[47, 48] - Rare Disease Total Revenue amounted to $43 billion in H1 2025, a 3% increase[58, 59] Geographical Distribution - US accounted for 43% of Total Revenue in H1 2025, amounting to $11955 million[12] - Europe contributed 21% of Total Revenue in H1 2025, totaling $5825 million[12] - China represented 13% of Total Revenue in H1 2025, with $3515 million[12]

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA England Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is sub ...

Core Viewpoint - The CEO of AstraZeneca indicated that the Trump administration is considering proposals to lower drug prices [1] Group 1 - AstraZeneca's CEO highlighted the ongoing discussions with the Trump administration regarding drug pricing strategies [1]

阿斯利康首席执行官：美国政府未承诺该公司可避免关税。 ...

"我们看好中国创新潜力，继续扩大在华研发布局。"阿斯利康方面披露，3月，公司宣布了一笔25亿美 元的在华投资计划，其中包括在北京建立第六个全球战略研发中心。目前，阿斯利康全球六大战略研发 中心已有两个落户中国。 分地区来看，上半年，阿斯利康美国市场收入119.7亿美元，同比增长12%，新兴市场收入76.97亿美 元，同比增长12%，其中中国区收入35.15亿美元，同比增长5%，占全球收入的12%以上。 格隆汇7月29日｜阿斯利康(AZN.US)今日公布2025年上半年业绩，实现总营收280.45亿美元，同比增长 11%，其中产品收入279.63亿美元，同比增长11%。 ...

7月29日，阿斯利康公布2025年上半年业绩，实现总营收280.45亿美元，同比增长11%，其中产品收入 279.63亿美元，同比增长11%。分地区来看，上半年，阿斯利康美国市场收入119.7亿美元，同比增长 12%，新兴市场收入76.97亿美元，同比增长12%，其中中国区收入35.15亿美元，同比增长5%，占全球 收入的12%以上。"我们看好中国创新潜力，继续扩大在华研发布局。"阿斯利康方面披露，3月，公司 宣布了一笔25亿美元的在华投资计划，其中包括在北京建立第六个全球战略研发中心。目前，阿斯利康 全球六大战略研发中心已有两个落户中国。(21世纪经济报道) ...

Core Viewpoint - AstraZeneca has reported strong second-quarter earnings, driven by its innovative cancer drugs, exceeding Wall Street expectations and indicating a positive outlook for the global innovative drug sector [1][2]. Financial Performance - AstraZeneca's total revenue for Q2 increased by 12% year-on-year to $14.5 billion, surpassing Wall Street forecasts [1]. - Adjusted earnings per share for Q2 rose by 10% to $2.17, also exceeding analyst expectations [1]. - For the first half of the year, total revenue grew by 9% to $28 billion, with adjusted earnings per share increasing by 16% to $4.66, both above market expectations [1]. Product Performance - The strong demand for cancer drugs Tagrisso and Imfinzi significantly contributed to AstraZeneca's revenue, with the oncology portfolio generating $6.3 billion in Q2, far exceeding analyst predictions [2][3]. - Tagrisso generated $1.8 billion in revenue for Q2, a 13% year-on-year increase, while Imfinzi brought in $1.5 billion, with a 30% growth [3][5]. Market Strategy - Under CEO Pascal Soriot, AstraZeneca is focusing on oncology and expanding its presence in the U.S. market, committing to invest $50 billion in production and R&D by 2030 [3]. - The company is also developing treatments for cardiovascular diseases and obesity, aiming to create next-generation weight loss drugs [3]. Future Prospects - The upcoming late-stage clinical trial results for the potential blockbuster drug Datroway are expected to be a key catalyst for AstraZeneca's stock performance, although results have been delayed until next year [2][6]. - Datroway is positioned as a new frontline treatment for patients with EGFR-resistant and immune-resistant lung cancer, with a clear commercialization path in non-small cell lung cancer [6].

Core Viewpoint - The article discusses the significant growth and strategic partnerships of the Chinese biotech company, HAPO, particularly through its collaborations with global pharmaceutical giants like AstraZeneca and Otsuka Pharmaceutical, highlighting the potential and challenges of its business development (BD) model [1][3][4]. Group 1: Financial Performance - HAPO reported a projected profit of approximately $68 million to $74 million for the six months ending June 30, 2025, compared to a revenue of about $2.37 million and a profit of approximately $140,000 in the first half of 2024, indicating a more than 47-fold increase in profit [1]. - The substantial profit increase is primarily attributed to the large upfront payment from AstraZeneca, validating the value of HAPO's technology platform and BD capabilities [1][5]. - The company has completed 17 BD transactions, establishing itself as a leader in China's biotech sector for BD activities [4]. Group 2: Strategic Partnerships - HAPO's collaboration with AstraZeneca includes a $1.05 billion equity investment and a total potential payment of up to $4.4 billion based on research and commercial milestones [3]. - The partnership allows AstraZeneca to access HAPO's proprietary Harbour Mice® technology platform for multiple therapeutic projects, enhancing HAPO's market position [3]. - A second significant partnership with Otsuka Pharmaceutical focuses on developing a dual-specific T cell engager for autoimmune diseases, with a total deal value of up to $670 million [4]. Group 3: Challenges and Risks - Despite impressive financial results, HAPO faces challenges in commercializing its core self-developed products, particularly in a competitive landscape with other companies also seeking market approval for similar products [6][7]. - The realization of milestone payments remains uncertain, as future payments depend on the clinical development progress of licensed products [6]. - The reliance on large BD transactions poses risks, as the ability to consistently secure high-value deals may be limited, impacting the company's long-term profitability [6][8]. Group 4: Long-term Outlook - Analysts emphasize the importance of HAPO's ability to develop and commercialize its own products to achieve sustainable profitability, rather than solely relying on BD transactions [7][8]. - The company must maintain its technological edge and produce high-quality projects to remain competitive in the evolving biotech landscape [7][8]. - Time will be the ultimate test for HAPO to transition from being a "BD king" to a "profit king" in the industry [9].

Financial Performance - AstraZeneca reports better-than-expected sales [1] - AstraZeneca's profit is rising for the second quarter [1] Product Performance - Growth is spurred by its stable of cancer medicines [1]

Industry Overview - The second-quarter 2025 reporting cycle for the Medical sector is commencing, with most firms expected to release earnings results in the next two weeks, primarily consisting of pharma/biotech and medical device companies [1] - The earnings season for the drug and biotech sector began in mid-July, highlighted by Johnson & Johnson's strong performance, which exceeded earnings and sales estimates, leading to raised revenue and earnings expectations for the year [1] Company Performance - Novartis surpassed second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs, prompting an upward revision of its annual guidance for core operating income [2] - Roche experienced solid growth in the first half of 2025, with high demand for key drugs offsetting declines in legacy drug sales [2] - As of July 23, 15% of companies in the Medical sector, representing 27.2% of the sector's market capitalization, reported quarterly earnings, with 88.9% outperforming earnings estimates and 100% beating revenue estimates [3] - Overall, second-quarter earnings for the Medical sector are projected to increase by 0.9%, while sales are expected to rise by 7.9% compared to the previous year [3] Upcoming Earnings Reports - Merck, AstraZeneca, Bristol Myers, AbbVie, and Moderna are scheduled to release their quarterly results this week [4] - Merck has a strong earnings track record, beating estimates in the last four quarters with an average surprise of 3.82% [5] - AstraZeneca has a mixed earnings history, beating estimates in three of the last four quarters, with an average surprise of 4.24% [8] - Bristol Myers has consistently beaten earnings estimates, with an average surprise of 20.16% over the last four quarters [11] - AbbVie has also maintained a strong track record, beating estimates in the last four quarters with an average surprise of 2.55% [13] - Moderna has an excellent earnings history, with an average surprise of 31.60% in the last four quarters [15] Sales Drivers - Merck's growth in the second quarter is likely attributed to increased sales of its cancer drug Keytruda, driven by additional indications and patient demand [7] - AstraZeneca's sales are expected to be bolstered by strong demand for its cancer and diabetes medications [10] - Bristol Myers' revenue may be impacted by declines in legacy drug sales, but growth products are expected to partially offset this decline [12] - AbbVie's revenue is anticipated to be driven by strong sales of key drugs and contributions from newer products [14] - Moderna's revenues are expected to be influenced by sales of its COVID-19 vaccine, Spikevax, while the focus is shifting to updates on its broader pipeline [16]